New Clinical Trials and Therapeutic Advances with Faricimab and Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: A Durability-Oriented Comparative Perspective. [PDF]
BiomedicinesMenna F +5 more
europepmc +1 more source
Different aflibercept regimens for wet age-related macular degeneration: A systematic review and network meta-analysis. [PDF]
J Chin Med AssocChen YS +5 more
europepmc +1 more source
Adverse Events Reported with Standard-Dose and High-Dose Aflibercept: A FAERS Pharmacovigilance Study. [PDF]
Vision (Basel)Prasad M, Ramsey DJ.
europepmc +1 more source
Switching to High-Dose Aflibercept (8 mg) with Pro Re Nata Reduces Treatment Burden in Diabetic Macular Edema: A Real-World Pilot Study. [PDF]
J Clin MedFunatsu M +10 more
europepmc +1 more source
Correlations between SS-OCT and OCT angiography biomarkers in treatment-naïve neovascular AMD during aflibercept therapy: a prospective study. [PDF]
Int J Retina VitreousRezende MP +5 more
europepmc +1 more source
Ocular Half-Life: What it Does and Does Not Mean for Intravitreal Anti-angiogenic Drug Durability. [PDF]
Ophthalmol TherAvery R +5 more
europepmc +1 more source
Measurement of Acute Intraocular Pressure Elevation Immediately After Intravitreal Anti-VEGF Injection and Analysis of Prefilled Syringe Accuracy. [PDF]
Clin OphthalmolItoh K, Negishi M.
europepmc +1 more source
Fellow-eye effect of intravitreal aflibercept 8mg in a patient with bilateral refractory nAMD: a case report and literature review. [PDF]
BMC OphthalmolZhang J +5 more
europepmc +1 more source